Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
'Aggressive' pricing helps Merck steal hep C share with newcomer Zepatier

Merck & Co. has yet to report first-quarter earnings, so industry watchers still don’t know exactly how much market share the company’s new hep C combo treatment, Zepatier, has scored since winning approval in late January. But so far, comments from its competitors suggest it’s doing pretty well for itself.

Published
15 hours ago
From
Fierce Pharma
European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two doses of Descovy® (emtricitabine and tenofovir alafenamide 200/10 mg and 200/25 mg; F/TAF), a fixed-dose combination for the treatment of HIV-1 infection. Descovy is Gilead’s second TAF-based therapy to receive marketing authorization in the European Union.

Published
25 April 2016
From
Gilead press release
Gilead Statement on the Approval of PrEP in Peru

Gilead Sciences, Inc. is pleased to share that the Peru Ministry of Health has approved the use of once- daily oral Truvada® (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) as pre-exposure prophylaxis (PrEP), in combination with safer sex practices, to help reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk .

Published
14 April 2016
From
Gilead Sciences
Innovative new programme set to treat 10,000 patients co-infected with hepatitis C and HIV in Africa and Asia

The World Hepatitis Alliance welcomes the announcement of a new programme initiated by the Clinton Health Access Initiative, Inc. (CHAI) and AmeriCares that aims to treat 10,000 co-infected HIV and hepatitis C patients in Africa and Asia with new hepatitis C treatment Daklinza (daclatasvir).

Published
14 April 2016
From
World Hepatitis Alliance
PrEP Pricing Problems

A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them

Published
02 April 2016
From
TAG
Greed and the Necessity for Regulation

The story of U.S. drug pricing run amok isn’t just about corporate arrogance and avarice—it is also about government permissiveness and inaction

Published
02 April 2016
From
TAG
GSK eases IP rights for poorest countries, considers patent pooling for cancer

As the United Nations Secretary General’s High-Level Panel on Access to Medicines initiative continues its work, the GlaxoSmithKline company today announced steps to further help bring innovative medicines to poor countries.

Published
02 April 2016
From
Intellectual Property Watch
Mortgages For Expensive Health Care? Some Experts Think It Can Work

A Massachusetts Institute of Technology economist and Harvard oncologist have a proposal to get highly effective but prohibitively expensive drugs into consumers’ hands: health care installment loans.

Published
29 March 2016
From
Kaiser Health News
Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments

Two years after two new drugs to treat tuberculosis—the first in over 50 years—were conditionally approved for use, only 2% of the 150,000 people who need them have been able to access them, according to Médecins Sans Frontières (MSF).

Published
24 March 2016
From
Médecins Sans Frontières
Merck Wins Chance for Royalties on Gilead’s Hepatitis C Cure

Merck & Co. won a sweeping jury verdict that allows it to seek royalties from Gilead Sciences Inc. for the drugs that have dominated the hepatitis C market with $20 billion in U.S. sales since 2013. Jurors Tuesday embraced Merck’s claims that its scientists were responsible for early breakthroughs that led to the development of the Sovaldi and Harvoni medicines that propelled Gilead to become the world’s largest biotechnology firm by market valuation.

Published
24 March 2016
From
Bloomberg
← First12345...86Next →

Filter by country